Supernus Announces Second Quarter 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015
August 11, 2014 5:10 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.08, may not compare to the analyst estimate of ($0.16). Revenue for the quarter came in at $29.67 million versus the consensus estimate of $19.85 million.
Financial Guidance
With the recognition of royalty revenues of $30 million in July, the Company is... More



